GeoVax Labs’ (GOVX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research report sent to investors on Friday,Benzinga reports. The firm currently has a $9.00 target price on the stock.

Separately, Wall Street Zen downgraded shares of GeoVax Labs from a “hold” rating to a “sell” rating in a report on Monday, July 21st. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $8.50.

GeoVax Labs Stock Performance

Shares of GOVX stock opened at $0.65 on Friday. GeoVax Labs has a 1 year low of $0.43 and a 1 year high of $3.88. The business’s fifty day moving average is $0.72 and its 200-day moving average is $0.89. The stock has a market cap of $10.29 million, a PE ratio of -0.32 and a beta of 3.57.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings data on Monday, July 28th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.06. The business had revenue of $0.85 million during the quarter, compared to analyst estimates of $0.37 million. GeoVax Labs had a negative return on equity of 408.80% and a negative net margin of 403.88%. Equities research analysts predict that GeoVax Labs will post -4.49 earnings per share for the current year.

Hedge Funds Weigh In On GeoVax Labs

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Northern Trust Corp acquired a new stake in GeoVax Labs during the 4th quarter worth about $29,000. Citadel Advisors LLC purchased a new position in shares of GeoVax Labs in the fourth quarter worth approximately $104,000. Armistice Capital LLC acquired a new stake in shares of GeoVax Labs during the first quarter valued at approximately $703,000. Finally, Jane Street Group LLC purchased a new stake in shares of GeoVax Labs in the 1st quarter valued at approximately $27,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.